Date: 2017-02-10
Type of information: Private placement
Company: Santhera Pharmaceuticals (Switzerland)
Investors:
Amount: CHF 60 million (€ 56.18 million)
Funding type: private placement
Planned used:
- Santhera Pharmaceuticals intends to use the net proceeds from this placement primarily to fund the commercialization of Raxone® in the currently approved indication, to prepare the market entry and commercial launch in subsequent indications, for investment into further clinical trials with Raxone® and for other corporate purposes.
Others:
- • On February 10, 2017, Santhera Pharmaceuticals announced the successful placement of CHF 60 million senior unsecured convertible bonds due 2022. The convertible bonds have a 5-year maturity and a coupon of 5.00% per annum. The conversion price was fixed at CHF 86.4006, representing a premium of 20% over the volume weighted average price of the shares between the launch and pricing of the convertible bonds. The convertible bonds are issued at 100% of their principal amount and, unless previously redeemed, converted or repurchased and cancelled, will mature on February 17, 2022, at 100% of their principal amount.
Bank am Bellevue and Kepler Cheuvreux acted as Joint Bookrunners on the Convertible Bond offering.
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Is general: Yes